Company Information

Company Information2024-10-05T12:40:24+09:00

Vision

Goodbye. Diabetes.
Towards the development of a treatment that completely cures diabetes.
The goal is to completely cure the disease, not just treat it symptomatically.

Greetings from the Chief Executive Officer

The origins of Biozipcode Inc. date back to 2015, when StudioMakyu Inc. (led by CEO Fumihisa Kojima) established a research lab at the Bio-Innovation Center as part of a joint research project with the Department of Biochemistry and Molecular Biology at Shiga University of Medical Science (former Professor Hideto Kojima, currently Special Professor of the Regenerative Medicine Course).

In addition to traditional In Vivo (in living organisms) and In Vitro (in test tubes) research, we also supported In Silico (computer simulation) research and development. This included the use of bioinformatics tools such as BLAST, development of proprietary software, and large-scale computing with GPGPU technology.

In January 2022, Biozipcode Inc. was established, succeeding and take over the joint research with StudioMakyu. In April of the same year, a joint research lab for the “Regenerative Medicine Frontier Course” was set up at Shiga University of Medical Science, where we have been developing new therapies to cure difficult diseases, including diabetes. Additionally, we are working on the development of new treatments using cell-targeting peptides (Biozipcode).

Diabetes is widely regarded as a disease that cannot be cured once developed. Our company has been dedicated to scientifically uncovering why it is deemed incurable and finding solutions to develop treatments.

In June 2023, groundbreaking research on curing diabetes was published in a scientific journal. Following this success, we increased our joint research funding and have been accelerating our research. We are now incorporating capital from pharmaceutical companies and preparing for the societal implementation of our findings.

Biozipcode, Inc.

Fumihisa Kojima

Biozipcode, Inc.

Company Name Biozipcode, Inc.
Established January 2022 (Reiwa 4th year)
Capital 70 million yen
Head Office Location Otsu, Shiga, Tsukinowa-cho, Shiga University of Medical Science Biomedical Innovation Facility
Representative President and CEO Fumihisa Kojima
Advisors Professor Hideto Kojima, Shiga University of Medical Science
Atsushi Kumada, Former Member of the House of Representatives
Main Business 1. Research, development, and sales of pharmaceuticals, including diabetes treatment drugs.
2. Research and development of technologies for delivering drugs and other substances to specific cells based on cell-related databases.
3. Contract development of systems and data analysis utilizing technology mentioned in 2.
4. Research, development, and sales of pesticides and insecticides that do not cause environmental pollution, targeting non-human animals and plants, utilizing technology mentioned in 2.
5. Licensing and sales of patent rights and other rights related to the above.
6. All businesses incidental to the above.

Karahashi Bridge in Seta, Otsu City

About therapeutic drugs that completely cure diabetes

Approximately 500 million people worldwide live with diabetes

One in 11 adults and one in five elderly people have diabetes.
Diabetes and its complications account for more than 10% of the world’s total medical costs, costing nearly 100 trillion yen annually, putting pressure on the global medical economy.

Currently, even specialists believe that diabetes is an incurable disease once it develops.
Diabetes treatment is a coping therapy called blood sugar control, and there is still no “cure drug” yet.

A complete cure has been demonstrated in mice through oral administration or intravenous injection.
It has been announced that diabetes is not directly caused by the pancreas, but rather by abnormalities in hematopoietic stem cells in the bone marrow.

About Biozipcode (Cell Targeting Technology)

A 7-Digit Amino Acid Sequence Modeled After Japanese Postal Codes

We are developing an innovative system that accurately delivers drugs to specific cells using a 7-digit amino acid sequence similar to Japanese postal codes. This technology ensures that the drug reaches only the target cells, significantly reducing the risk of side effects and allowing the drug to work precisely where it’s needed.

Using the new transportation system called “Biozipcode,” it is possible to develop drugs that act directly on specific target cells. This system aims to deliver drugs precisely to the target cells.

Pathological stem cells that have become dysfunctional often hide within niches to avoid contact with drugs. However, recent methods have been developed to activate these niches, moving the pathological stem cells to accessible areas. The Biozipcode technology can be used with new drugs or previously developed drugs that could not be used due to side effects. Nano-drones with the target code will ensure that drugs are delivered only to the target cells.

FAQ

FAQ

We will answer frequently asked questions regarding BioZipcord’s business. If you have any questions that are not listed in the FAQ, please feel free to contact us using the inquiry form.

For FAQs regarding individual projects, please see the “Frequently Asked Questions” page.

What is the long-term strategy for growth and expansion in domestic and international markets?2024-01-21T20:33:51+09:00

The expansion into international markets is being considered based on the regulations and market demands of each country. Diabetes is a global health issue, and international demand is anticipated. Patent licensing agreements and other preparations are being made in each country before the completion of international patent transfers.

Note: The term ‘domestic’ refers to within Japan.

Are clinical trials and research for diabetes cure methods and products ongoing, and what have been the results so far?2024-01-21T20:33:06+09:00

The new drug targets all patients, including those with Type 1 and Type 2 diabetes, and is effective for diabetes complications. It is currently in the planning stage of clinical trials. Animal experiments are being conducted on mice and also on larger animals.

What are the main research and development areas, and how do they align with the company’s long-term goals?2024-01-21T20:32:23+09:00

The main research and development areas are:

(1) Developing drugs that completely cure diabetes and its complications, focusing on specific cells that are the root cause of diabetes, and working on new diagnostic and treatment drugs.

(2) Advancing new ventures in the application of Biozipcode technology (cell targeting technology).

Could you tell us about the current capital and sources of funding?2024-04-12T17:23:45+09:00

Biozipcode, Inc. was established in January of Reiwa year 4th (2022) with a capital of 70 million yen. Funding has been provided by Representative Director Fumihisa Kojima and Studio Makyu Co., Ltd, along with their collaborating companies.

The development costs for new drugs usually range from several tens of million to hundred millions of USD, and funding is planned through investors, VCs, government and private grants, and partnerships for joint research.

How is Biozipcode, Inc. addressing untreated diseases like diabetes?2024-01-21T20:28:40+09:00

Biozipcode, Inc. is dedicated to tackling untreated diseases such as diabetes and providing fundamental treatment methods. To achieve this goal, the company conducts research using cutting-edge scientific technology to delve into the essence of diseases.

It focuses on achieving a complete cure for diabetes, emphasizing scientific discovery and societal understanding and support.

About the establishment of Biozipcode, Inc.2024-04-22T14:40:59+09:00

The establishment of Biozipcode, Inc. began around 2015, as part of a joint research initiative between StudioMakyu Co., Ltd. (led by Representative Director Fumihisa Kojima) and the Department of Biochemistry and Molecular Biology at Shiga University of Medical Science (formerly led by Professor Hideto Kojima, now a special professor).

StudioMakyu Co., Ltd. initially supported both traditional wet lab research (In Vivo and In Vitro) as well as In Silico research and development. This included using bioinformatics tools like BLAST, developing proprietary software, and performing large-scale computations with GPGPU.

In January 2022, Biozipcode, Inc. was established to continue the joint research with StudioMakyu Co., Ltd. . Subsequently, in April 2022, a joint research lab for “Regenerative Medicine Development Course” was set up at Shiga University of Medical Science, focusing on developing new curative methods for intractable diseases including diabetes, and establishing new treatments using cell-targeting peptides (Biozipcode).

Merchant Bankers Co., Ltd. promised an investment of 100 million yen and assistance in raising funds of approximately 10 billion yen. However, due to delays and refusal in the payment of joint research expenses, citing reasons like delays in peer review of lab papers, unpaid bills to the patent office for patent applications, and threats of termination of the joint research agreement, Fumihisa Kojima bought back all shares in exchange for the 40 million yen disbursed by Merchant Bankers Co., Ltd. and the costs of patent applications. He aimed to continue the joint research course. Currently, over 130 million yen is being spent on research and related expenses.

In June 2023, a study titled “Complete remission of diabetes with a transient HDAC inhibitor and insulin in streptozotocin mice” was published in Communications Biology, leading to an increase in joint research funds by Biozipcode, Inc. and accelerating the research. Plans are in place to continue research beyond the fiscal year 2024 and to consider business partnerships and joint ventures with pharmaceutical companies.

For the release from Merchant Bankers Co., Ltd., please refer to this URL.
https://www.nikkei.com/nkd/disclosure/tdnr/20230227518853/

Are you interested in our business?

Are you interested in our business?

Medical professionals, investors, and members of the press, please feel free to contact us by filling out the necessary information in the email form. Our representatives will get back to you promptly.

Medical professionals, investors, and members of the press, please feel free to contact us by filling out the necessary information in the email form. Our representatives will get back to you promptly.

KIYAN Group and Collaborating Research Institutions

KIYAN PHARMA Co., Ltd

KIYAN PHARMA Co., Ltd.

KIYAN MEDICAL Co., Ltd.

KIYAN MEDICAL Co., Ltd.

Biozipcode, Inc.

Biozipcode, Inc.

Shiga University of Medical Science, Department of Regenerative Medicine

Shiga University of Medical Science, Dep. of Regenerative Medicine

Biozipcode, Inc.

We aim to completely cure diseases rather than just offering symptomatic treatments. We focus on developing a cure for diabetes and a technology that delivers medication to specific cells (cell targeting technology called “Biozipcode”).

Learn More About Us

Contact Us

Biozipcode, Inc.

TEL:
+81-50-5534-7865

E-MAIL:
info@biozipcode.com

ADDRESS:
Seta Tsukiwa-cho, Otsu City, Shiga Prefecture
Biomedical Innovation Center, Shiga University of Medical Science, 520-2121

Languages

© Copyright 2024 Biozipcode, Inc. All Rights Reserved.

Go to Top